Skip to main content
DEINOVE logo

DEINOVE — Investor Relations & Filings

Ticker · ALDEI ISIN · FR0010879056 LEI · 969500BEJSRFER0F2K08 PA Professional, scientific and technical activities
Open in API
Filings indexed 300 across all filing types
Latest filing 2020-10-01 Interim / Quarterly Rep…
Country FR France
Listing PA ALDEI

About DEINOVE

https://www.deinove.com

DEINOVE is a biotechnology company that discovers, develops, and produces high-value compounds derived from rare bacteria and microorganisms, often referred to as 'microbial dark matter'. Leveraging a proprietary technology platform, the company harnesses the metabolic potential of extremophilic bacteria, such as Deinococcus, to create innovative solutions. Its primary applications are focused on developing novel bio-based active ingredients, including carotenoids, for the cosmetics sector, and discovering new antibiotics to address the global challenge of antimicrobial resistance.

Recent filings

Filing Released Lang Actions
Inside Information / News release on accounts, results
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive report detailing the company's financial performance, operational progress, and management discussion for the first half of 2020. It includes consolidated financial statements (Profit and Loss, Cash position), management commentary on business trends, and updates on R&D programs. Since it covers a period shorter than a full fiscal year and contains substantive financial data and analysis, it is classified as an Interim/Quarterly Report. H1 2020
2020-10-01 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release issued by the biotechnology company DEINOVE. It provides an update on the progress of a Phase II clinical trial for their antibiotic candidate DNV3837 in the United States. It discusses the clinical context, the impact of COVID-19 on the trial, and provides background information on the company's pipeline and business activities. As it is a corporate announcement regarding operational/clinical progress rather than a formal financial report, a regulatory filing, or a specific investor presentation, it falls under the general category of regulatory/corporate announcements. FY 2020
2020-07-15 French
Inside Information / Other news releases
Legal Proceedings Report Classification · 1% confidence The document is a press release from DEINOVE, dated July 15, 2020, providing an update on the continuation of its Phase II clinical trial for the antibiotic candidate DNV3837, despite the COVID-19 context. It details the scientific background, the trial structure, and includes quotes from management and external bodies (WHO). This content structure—a detailed operational and scientific update on a specific drug development stage—is characteristic of an Investor Presentation (IP) or a detailed press release that functions as one, rather than a formal regulatory filing like a 10-K, an Earnings Release (ER) which focuses on financial metrics, or a simple announcement of a report (RPA). Given the depth of scientific and clinical trial information aimed at investors, Investor Presentation (IP) is the most appropriate classification, as it serves to inform the investment community about key operational progress.
2020-07-15 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is titled "Bilan semestriel du contrat de liquidité DEINOVE confié à KEPLER CHEUVREUX" (Semi-annual balance sheet of the DEINOVE liquidity contract entrusted to KEPLER CHEUVREUX) and reports the status of shares and cash held under a liquidity contract as of June 30, 2020. This type of filing, which details the status of a market-making or liquidity agreement, is a specific regulatory disclosure related to market operations, but it does not fit neatly into the primary categories like 10-K, ER, or IR. It is an announcement concerning market stability/share management. Since it is a specific regulatory disclosure that doesn't match the other defined categories (like dividend, capital change, or director dealing), it falls best under the general 'Regulatory Filings' category (RNS) as a miscellaneous, required market announcement, or potentially 'CAP' (Capital/Financing Update) due to its relation to share liquidity, but RNS is a safer fallback for non-standard regulatory updates. Given the context of market operations reporting, RNS is the most appropriate general regulatory filing code.
2020-07-01 French
Inside Information / Other news releases
Capital/Financing Update Classification · 1% confidence The document announces the 'ISSUANCE OF A 3RD TRANCHE OF €1.5 MILLION OF NOTES CONVERTIBLE INTO NEW SHARES'. This action directly relates to the company's financing activities and capital structure, specifically raising capital through convertible notes. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not an earnings release, an annual report, or a general regulatory filing, but a specific announcement about raising capital.
2020-06-17 English
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 1% confidence The document is a press release dated June 17, 2020, announcing the issuance of a 3rd tranche of convertible bonds (OCA) for €1.5 million to reinforce immediate cash flow. This action directly relates to the company's financing activities and capital structure. Based on the definitions, the category 'Capital/Financing Update' (CAP) is the most appropriate classification for an announcement detailing the issuance of debt/convertible instruments to raise capital.
2020-06-17 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.